Press "Enter" to skip to content

Interline Therapeutics Raises Money in financing round

By Willie Wise on May 19, 2021

Interline Therapeutics, a Foresite Labs-incubated company, announced on Thursday that it had raised $92 million in a financing round which is co-led by Foresite Capital and ARCH Venture Partners. The funding, launched by the company, will be used toward the development of therapies that correct dysfunctional protein communities to treat various diseases.

The money earned in the financing round is a combination of seed and Series A funding. The company said that its proceeds will be funnelled to facilitate the expansion of its research platform and advance a total of six preclinical therapeutic programs.The Therapeutics will use genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities to construct a precision medicine platform focused on genomics, protein communities, and modulators of these communities.

These three pillars form the basis of the company’s overall strategy, which has seen collaborative support from the likes of the University of California, San Francisco, and Memorial Sloan Kettering Cancer Center. The platform will help the company identify new treatments that target genetically validated signalling pathways while ensuring the therapeutic candidates comprehensively correct dysfunctional disease networks.

Interline Therapeutics Co-Founder and Chief Executive Officer, Zachary Sweeney, is joined by company leaders who boast clinical development experience at Amgen, Genentech, Novartis, Denali Therapeutics and Nurix. Vikram Bajaj, PhD, Co-Founder and CEO of Foresite Labs said that by creating a platform to discover, understand and re-engineer protein interactions, we will find new approaches to treat debilitating diseases. Zach and the Interline team possess an incredible breadth of experience, and we are thrilled to help accelerate Interline’s growth.

The company announced that healthcare tech company Aetion closed a $110 million Series C funding round with help from Foresite Capital, in addition to Warburg Pincus and B Capital. Aetion has raised $212 million, which is being harnessed to further establish the company’s stance in the real-world evidence space.

Published in Biotechnology and News

Willie Wise

Backed by a strong educational background with a degree in Biotechnology, Greenville Technical College, Willie D. Wise is an asset to The Healthcare News and is rightfully placed as the Chief Editor, owing to his vast experience in technical writing, marketing, and strategic planning. To hone his job skills in journalism, Wise has also completed a degree course in journalism from the University of South Carolina-Columbia. He is highly skilled with the art of news presentation and is adept in an editorial role with excellent time management and leadership qualities at his disposal. He ensures the best delivery from his team of writers and ensures excellent performance by his team. Besides his current job as the editor-in-chief at The Healthcare News, he is a regular writer for the biotechnology category. Given his intense interest in the field, his core career centers around writing which he does with complete dexterity. As a writer, he ensures appropriate title selection besides developing authentic, market-relevant content ideal for business discretion and also to suit promotional and marketing strategies of TheHealthcareNews. His writing style not only remains informative but also is high on lucidity to entice reader focus for longer. Crude facts and statistical details are also presented simplistically to connect with readers' grasping capabilities.

More from BiotechnologyMore posts in Biotechnology »
More from NewsMore posts in News »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *